Journal of Gastrointestinal Surgery

, Volume 15, Issue 5, pp 708–718 | Cite as

Barrett’s Esophagus: A Review of the Literature

  • Erin W. Gilbert
  • Renato A. Luna
  • Vincent L. Harrison
  • John G. Hunter
Review Article

Abstract

Barrett’s esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia of the tubular esophagus that results from chronic gastroesophageal reflux. Which patients are at risk of having BE and which are at further risk of developing EAC has yet to be fully established. Many aspects of the management of BE have changed considerably in the past 5 years alone. The aim of this review is to define the critical elements necessary to effectively manage individuals with BE. The general prevalence of BE is estimated at 1.6–3% and follows a demographic distribution similar to EAC. Both short-segment (<3 cm) and long-segment (≥3 cm) BE confer a significant risk for EAC that is increased by the development of dysplasia. The treatment for flat high-grade dysplasia is endoscopic radiofrequency ablation therapy. The benefits of ablation for non-dysplastic BE and BE with low-grade dysplasia have yet to be validated. By understanding the intricacies of the development, screening, surveillance, and treatment of BE, new insights will be gained into the prevention and early detection of EAC that may ultimately lead to a reduction in morbidity and mortality in this patient population.

Keywords

Barrett’s esophagus Specialized intestinal metaplasia Esophageal adenocarcinoma Gastroesophageal reflux Endoscopic therapy Radiofrequency ablation 

References

  1. 1.
    H. Pohl and H. G. Welch. (2005, Jan 19). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97(2), pp. 142–146. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=15657344.PubMedCrossRefGoogle Scholar
  2. 2.
    N. R. Barrett, "Chronic peptic ulcer of the oesophagus and 'oesophagitis'." Br. J. Surg., vol. 38, pp. 175–182, Oct, 1950.PubMedCrossRefGoogle Scholar
  3. 3.
    J. Hayward, "The lower end of the oesophagus." Thorax, vol. 16, pp. 36–41, Mar, 1961.PubMedCrossRefGoogle Scholar
  4. 4.
    K. K. Wang, R. E. Sampliner and Practice Parameters Committee of the American College of,Gastroenterology, “Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus.” Am. J. Gastroenterol., vol. 103, pp. 788–797, Mar, 2008.PubMedCrossRefGoogle Scholar
  5. 5.
    A. J. Cameron, A. R. Zinsmeister, D. J. Ballard and J. A. Carney, “Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings.” Gastroenterology, vol. 99, pp. 918–922, Oct, 1990.PubMedGoogle Scholar
  6. 6.
    J. Ronkainen, P. Aro, T. Storskrubb, S. E. Johansson, T. Lind, E. Bolling-Sternevald, M. Vieth, M. Stolte, N. J. Talley and L. Agreus, “Prevalence of Barrett’s esophagus in the general population: an endoscopic study.” Gastroenterology, vol. 129, pp. 1825–1831, Dec, 2005.PubMedCrossRefGoogle Scholar
  7. 7.
    X. Fan, N. Snyder. (2009, Mar). Prevalence of Barrett’s esophagus in patients with or without GERD symptoms: Role of race, age, and gender. Dig. Dis. Sci. 54(3), pp. 572–577. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18654849.PubMedCrossRefGoogle Scholar
  8. 8.
    M. A. Eloubeidi and D. Provenzale, “Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans.” J. Clin. Gastroenterol., vol. 33, pp. 306–309, Oct, 2001.PubMedCrossRefGoogle Scholar
  9. 9.
    R. V. Lord, K. Wickramasinghe, J. J. Johansson, S. R. Demeester, J. Brabender and T. R. Demeester, “Cardiac mucosa in the remnant esophagus after esophagectomy is an acquired epithelium with Barrett’s-like features.” Surgery, vol. 136, pp. 633–640, Sep, 2004.PubMedCrossRefGoogle Scholar
  10. 10.
    A. C. Ford, D. Forman, P. D. Reynolds, B. T. Cooper and P. Moayyedi, “Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus.” Am. J. Epidemiol., vol. 162, pp. 454–460, Sep 1, 2005.PubMedCrossRefGoogle Scholar
  11. 11.
    Z. R. Edelstein, D. C. Farrow, M. P. Bronner, S. N. Rosen and T. L. Vaughan, “Central adiposity and risk of Barrett’s esophagus.” Gastroenterology, vol. 133, pp. 403–411, Aug, 2007.PubMedCrossRefGoogle Scholar
  12. 12.
    Z. R. Edelstein, M. P. Bronner, S. N. Rosen and T. L. Vaughan. (2009, Apr). Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: A community clinic-based case-control study. Am. J. Gastroenterol. 104(4), pp. 834–842. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19319131.PubMedCrossRefGoogle Scholar
  13. 13.
    V. N. Shirvani, R. Ouatu-Lascar, B. S. Kaur, M. B. Omary and G. Triadafilopoulos, “Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.” Gastroenterology, vol. 118, pp. 487–496, Mar, 2000.PubMedCrossRefGoogle Scholar
  14. 14.
    D. Das, A. P. Chilton and J. A. Jankowski, “Chemoprevention of oesophageal cancer and the AspECT trial,” Recent Results Cancer Res., vol. 181, pp. 161–169, 2009.PubMedCrossRefGoogle Scholar
  15. 15.
    L. A. Anderson, S. J. Murphy, B. T. Johnston, R. G. Watson, H. R. Ferguson, K. B. Bamford, A. Ghazy, P. McCarron, J. McGuigan, J. V. Reynolds, H. Comber and L. J. Murray. (2008, Jun). Relationship between helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: Results from the FINBAR case-control study. Gut 57(6), pp. 734–739. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18025067.PubMedCrossRefGoogle Scholar
  16. 16.
    F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston and L. Murray. (2008, Aug 1). The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am. J. Epidemiol. 168(3), pp. 237–249. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18550563.PubMedCrossRefGoogle Scholar
  17. 17.
    P. Sharma, G. W. Falk, A. P. Weston, D. Reker, M. Johnston and R. E. Sampliner, “Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus.” Clin. Gastroenterol. Hepatol., vol. 4, pp. 566–572, May, 2006.PubMedCrossRefGoogle Scholar
  18. 18.
    Conio M. Blanchi S. Lapertosa G. Ferraris R. Sablich R. Marchi S. D’Onofrio V. Lacchin T. Iaquinto G. Missale G. Ravelli P. Cestari R. Benedetti G. Macrì G. Fiocca R. Munizzi F. Filiberti R, “Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.” Am. J. Gastroenterol., vol. 98, pp. 1931–1939, Sep, 2003.PubMedCrossRefGoogle Scholar
  19. 19.
    J. Theisen, H. J. Stein, H. J. Dittler, M. Feith, C. Moebius, W. K. Kauer, M. Werner and J. R. Siewert. (2002, Apr). Preoperative chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus. Surg. Endosc. 16(4), pp. 671–673. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11972212.PubMedCrossRefGoogle Scholar
  20. 20.
    A. P. Weston, P. Sharma, S. Mathur, S. Banerjee, A. K. Jafri, R. Cherian, D. McGregor, R. S. Hassanein and M. Hall, “Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis.” Am. J. Gastroenterol., vol. 99, pp. 1657–1666, Sep, 2004.PubMedCrossRefGoogle Scholar
  21. 21.
    J. Martinek, M. Benes, P. Brandtl, T. Hucl, M. Vasicek, L. Voska, V. Lanska, V. Nosek and J. Spicak. (2008, Sep). Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: A prospective cohort study. Endoscopy 40(9), pp. 711–716. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18698534.PubMedCrossRefGoogle Scholar
  22. 22.
    R. E. Rudolph, T. L. Vaughan, B. E. Storer, R. C. Haggitt, P. S. Rabinovitch, D. S. Levine and B. J. Reid, “Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.” Ann. Intern. Med., vol. 132, pp. 612–620, Apr 18, 2000.PubMedGoogle Scholar
  23. 23.
    P. T. Chandrasoma, R. Der, P. Dalton, G. Kobayashi, Y. Ma, J. Peters and T. Demeester, “Distribution and significance of epithelial types in columnar-lined esophagus.” Am. J. Surg. Pathol., vol. 25, pp. 1188–1193, Sep, 2001.PubMedCrossRefGoogle Scholar
  24. 24.
    P. T. Chandrasoma, R. Der, Y. Ma, P. Dalton and M. Taira, “Histology of the gastroesophageal junction: an autopsy study.” Am. J. Surg. Pathol., vol. 24, pp. 402–409, Mar, 2000.PubMedCrossRefGoogle Scholar
  25. 25.
    K. Takubo, J. Aida, Y. Naomoto, M. Sawabe, T. Arai, H. Shiraishi, M. Matsuura, C. Ell, A. May, O. Pech, M. Stolte and M. Vieth. (2009, Jan). Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum. Pathol. 40(1), pp. 65–74. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18755496.PubMedCrossRefGoogle Scholar
  26. 26.
    W. Liu, H. Hahn, R. D. Odze and R. K. Goyal. (2009, Apr). Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 104(4), pp. 816–824. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19293780.PubMedCrossRefGoogle Scholar
  27. 27.
    F. Paraf, J. F. Flejou, J. P. Pignon, F. Fekete and F. Potet, “Surgical pathology of adenocarcinoma arising in Barrett’s esophagus. Analysis of 67 cases.” Am. J. Surg. Pathol., vol. 19, pp. 183–191, Feb, 1995.PubMedCrossRefGoogle Scholar
  28. 28.
    R. J. Schlemper, R. H. Riddell, Y. Kato, F. Borchard, H. S. Cooper, S. M. Dawsey, M. F. Dixon, C. M. Fenoglio-Preiser, J. F. Flejou, K. Geboes, T. Hattori, T. Hirota, M. Itabashi, M. Iwafuchi, A. Iwashita, Y. I. Kim, T. Kirchner, M. Klimpfinger, M. Koike, G. Y. Lauwers, K. J. Lewin, G. Oberhuber, F. Offner, A. B. Price, C. A. Rubio, M. Shimizu, T. Shimoda, P. Sipponen, E. Solcia, M. Stolte, H. Watanabe and H. Yamabe, “The Vienna classification of gastrointestinal epithelial neoplasia.” Gut, vol. 47, pp. 251–255, Aug, 2000.PubMedCrossRefGoogle Scholar
  29. 29.
    P. J. de Jonge, M. van Blankenstein, C. W. Looman, M. K. Casparie, G. A. Meijer and E. J. Kuipers. (2010, Aug). Risk of malignant progression in patients with Barrett's oesophagus: A dutch nationwide cohort study. Gut 59(8), pp. 1030–1036. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20639249.PubMedCrossRefGoogle Scholar
  30. 30.
    W. L. Curvers, F. J. ten Kate, K. K. Krishnadath, M. Visser, B. Elzer, L. C. Baak, C. Bohmer, R. C. Mallant-Hent, A. van Oijen, A. H. Naber, P. Scholten, O. R. Busch, H. G. Blaauwgeers, G. A. Meijer and J. J. Bergman. (2010, Jul). Low-grade dysplasia in Barrett's esophagus: Overdiagnosed and underestimated. Am. J. Gastroenterol. 105(7), pp. 1523–1530, Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20461069.PubMedCrossRefGoogle Scholar
  31. 31.
    P. Gatenby, J. Ramus, C. Caygill, N. Shepherd, M. Winslet and A. Watson. (2009, Jun). Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: A population-based study of natural history. Histopathology 54(7), pp. 814–819. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19635100.PubMedCrossRefGoogle Scholar
  32. 32.
    G. S. Dulai, P. G. Shekelle, D. M. Jensen, B. M. Spiegel, J. Chen, D. Oh and K. L. Kahn, “Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort.” Am. J. Gastroenterol., vol. 100, pp. 775–783, Apr, 2005.PubMedCrossRefGoogle Scholar
  33. 33.
    M. Kerkhof, H. van Dekken, E. W. Steyerberg, G. A. Meijer, A. H. Mulder, A. de Bruine, A. Driessen, F. J. ten Kate, J. G. Kusters, E. J. Kuipers, P. D. Siersema and g. CYBAR study, “Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.” Histopathology, vol. 50, pp. 920–927, Jun, 2007.PubMedCrossRefGoogle Scholar
  34. 34.
    S. B. Edge, D. R. Byrd, C. C. Compton, A. G. Fritz, F. L. Greene and A. Tritti, Eds., AJCC Cancer Staging Manual. New York: Springer, 2009.Google Scholar
  35. 35.
    A. P. Barbour, M. Jones, I. Brown, D. C. Gotley, I. Martin, J. Thomas, A. Clouston and B. M. Smithers. (2010, Sep). Risk stratification for early esophageal adenocarcinoma: Analysis of lymphatic spread and prognostic factors. Ann. Surg. Oncol. 17(9), pp. 2494–2502. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20349213.PubMedCrossRefGoogle Scholar
  36. 36.
    P. Sharma, J. Dent, D. Armstrong, J. J. Bergman, L. Gossner, Y. Hoshihara, J. A. Jankowski, O. Junghard, L. Lundell, G. N. Tytgat and M. Vieth, “The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria.” Gastroenterology, vol. 131, pp. 1392–1399, Nov, 2006.PubMedCrossRefGoogle Scholar
  37. 37.
    R. Harrison, I. Perry, W. Haddadin, S. McDonald, R. Bryan, K. Abrams, R. Sampliner, N. J. Talley, P. Moayyedi and J. A. Jankowski, “Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies.” Am. J. Gastroenterol., vol. 102, pp. 1154–1161, Jun, 2007.PubMedCrossRefGoogle Scholar
  38. 38.
    B. J. Reid, P. L. Blount, Z. Feng and D. S. Levine, “Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia.” Am. J. Gastroenterol., vol. 95, pp. 3089–3096, Nov, 2000.PubMedCrossRefGoogle Scholar
  39. 39.
    A. May, E. Gunter, F. Roth, L. Gossner, M. Stolte, M. Vieth and C. Ell, “Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.” Gut, vol. 53, pp. 634–640, May, 2004.PubMedCrossRefGoogle Scholar
  40. 40.
    S. Ngamruengphong, V. K. Sharma and A. Das, “Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis.” Gastrointest. Endosc., vol. 69, pp. 1021–1028, May, 2009.PubMedCrossRefGoogle Scholar
  41. 41.
    H. C. Wolfsen, J. E. Crook, M. Krishna, S. R. Achem, K. R. Devault, E. P. Bouras, D. S. Loeb, M. E. Stark, T. A. Woodward, L. L. Hemminger, F. K. Cayer and M. B. Wallace. (2008, Jul). Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. Gastroenterology 135(1), pp. 24–31. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18442484.PubMedCrossRefGoogle Scholar
  42. 42.
    W. L. Curvers, L. A. Herrero, M. B. Wallace, L. M. Wong Kee Song, K. Ragunath, H. C. Wolfsen, G. A. Prasad, K. K. Wang, V. Subramanian, B. L. Weusten, F. J. Ten Kate and J. J. Bergman. (2010, Oct). Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 139(4), pp. 1106–1114. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20600033.PubMedCrossRefGoogle Scholar
  43. 43.
    J. M. Inadomi, R. Sampliner, J. Lagergren, D. Lieberman, A. M. Fendrick and N. Vakil, “Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.” Ann. Intern. Med., vol. 138, pp. 176–186, Feb 4, 2003.PubMedGoogle Scholar
  44. 44.
    A. Chak, A. Faulx, C. Eng, W. Grady, M. Kinnard, H. Ochs-Balcom and G. Falk, “Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia.” Cancer, vol. 107, pp. 2160–2166, Nov 1, 2006.PubMedCrossRefGoogle Scholar
  45. 45.
    M. Maffei and J. M. Dumonceau, “Transnasal esogastroduodenoscopy (EGD): comparison with conventional EGD and new applications,” Swiss Med. Wkly., vol. 138, pp. 658–664, Nov 15, 2008.PubMedGoogle Scholar
  46. 46.
    B. A. Jobe, J. G. Hunter, E. Y. Chang, C. Y. Kim, G. M. Eisen, J. D. Robinson, B. S. Diggs, R. W. O’Rourke, A. E. Rader, P. Schipper, D. A. Sauer, J. H. Peters, D. A. Lieberman and C. D. Morris, “Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison.” Am. J. Gastroenterol., vol. 101, pp. 2693–2703, Dec, 2006.PubMedCrossRefGoogle Scholar
  47. 47.
    K. J. Roberts, E. Harper, D. Alderson and M. Hallissey. (2010, Apr). Long-term survival and cost analysis of an annual Barrett's surveillance programme. Eur. J. Gastroenterol. Hepatol. 22(4), pp. 399–403. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19858726.PubMedCrossRefGoogle Scholar
  48. 48.
    T. Bright, A. Schloithe, J. A. Bull, R. J. Fraser, P. Bampton and D. I. Watson. (2009, Nov). Outcome of endoscopy surveillance for Barrett's oesophagus. ANZ J. Surg. 79(11), pp. 812–816. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20078532.PubMedCrossRefGoogle Scholar
  49. 49.
    R. C. Fitzgerald, I. T. Saeed, D. Khoo, M. J. Farthing and W. R. Burnham, “Rigorous surveillance protocol increases detection of curable cancers associated with Barrett’s esophagus.” Dig. Dis. Sci., vol. 46, pp. 1892–1898, Sep, 2001.PubMedCrossRefGoogle Scholar
  50. 50.
    M. F. Reed, G. Tolis Jr, B. H. Edil, J. S. Allan, D. M. Donahue, H. A. Gaissert, A. C. Moncure, J. C. Wain, C. D. Wright and D. J. Mathisen. (2005, discussion 1110–5; Apr). Surgical treatment of esophageal high-grade dysplasia. Ann. Thorac. Surg. 79(4), pp. 1110–1115. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=15797034.PubMedCrossRefGoogle Scholar
  51. 51.
    N. S. Buttar, K. K. Wang, T. J. Sebo, D. M. Riehle, K. K. Krishnadath, L. S. Lutzke, M. A. Anderson, T. M. Petterson and L. J. Burgart, “Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma.” Gastroenterology, vol. 120, pp. 1630–1639, Jun, 2001.PubMedCrossRefGoogle Scholar
  52. 52.
    E. E. Tseng, T. T. Wu, C. J. Yeo and R. F. Heitmiller, “Barrett’s esophagus with high grade dysplasia: surgical results and long-term outcome--an update.” J. Gastrointest. Surg., vol. 7, pp. 164–170, discussion 170–1; Feb, 2003.PubMedCrossRefGoogle Scholar
  53. 53.
    W. Zhu, H. D. Appelman, J. K. Greenson, S. R. Ramsburgh, M. B. Orringer, A. C. Chang and B. J. McKenna. (2009, Jul). A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am. J. Clin. Pathol. 132(1), pp. 94–100. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19864239.PubMedCrossRefGoogle Scholar
  54. 54.
    L. C. Hillman, L. Chiragakis, B. Shadbolt, G. L. Kaye and A. C. Clarke. (2008, Feb 15). Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment. Pharmacol. Ther. 27(4), pp. 321–326. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18047565.PubMedCrossRefGoogle Scholar
  55. 55.
    R. Ouatu-Lascar and G. Triadafilopoulos, “Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett’s esophagus.” Am. J. Gastroenterol., vol. 93, pp. 711–716, May, 1998.PubMedCrossRefGoogle Scholar
  56. 56.
    R. W. Yeh, L. B. Gerson and G. Triadafilopoulos, “Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus.” Dis. Esophagus, vol. 16, pp. 193–198, 2003.PubMedCrossRefGoogle Scholar
  57. 57.
    R. C. Fitzgerald, R. Lascar and G. Triadafilopoulos, “Review article: Barrett’s oesophagus, dysplasia and pharmacologic acid suppression,” Aliment. Pharmacol. Ther., vol. 15, pp. 269–276, Mar, 2001.PubMedCrossRefGoogle Scholar
  58. 58.
    J. D. Horwhat, D. Baroni, C. Maydonovitch, E. Osgard, E. Ormseth, E. Rueda-Pedraza, H. J. Lee, W. K. Hirota and R. K. Wong, “Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data.” Am. J. Gastroenterol., vol. 102, pp. 497–506, Mar, 2007.PubMedCrossRefGoogle Scholar
  59. 59.
    F. T. Peters, S. Ganesh, E. J. Kuipers, W. J. Sluiter, E. C. Klinkenberg-Knol, C. B. Lamers and J. H. Kleibeuker, “Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study,” Gut, vol. 45, pp. 489–494, Oct, 1999.PubMedCrossRefGoogle Scholar
  60. 60.
    D. M. Nguyen, H. B. El-Serag, L. Henderson, D. Stein, A. Bhattacharyya and R. E. Sampliner. (2009, Dec). Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 7(12), pp. 1299–1304. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19523538.PubMedCrossRefGoogle Scholar
  61. 61.
    H. B. El-Serag, T. V. Aguirre, S. Davis, M. Kuebeler, A. Bhattacharyya and R. E. Sampliner, “Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus.” Am. J. Gastroenterol., vol. 99, pp. 1877–1883, Oct, 2004.PubMedCrossRefGoogle Scholar
  62. 62.
    L. Monaco, A. Brillantino, F. Torelli, M. Schettino, G. Izzo, A. Cosenza and N. Di Martino, “Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors.” World J. Gastroenterol., vol. 15, pp. 334–338, Jan 21, 2009.PubMedCrossRefGoogle Scholar
  63. 63.
    C. B. Morgenthal, M. D. Shane, A. Stival, N. Gletsu, G. Milam, V. Swafford, J. G. Hunter and C. D. Smith, “The durability of laparoscopic Nissen fundoplication: 11-year outcomes.” J. Gastrointest. Surg., vol. 11, pp. 693–700, Jun, 2007.PubMedCrossRefGoogle Scholar
  64. 64.
    S. E. Attwood, L. Lundell, J. G. Hatlebakk, S. Eklund, O. Junghard, J. P. Galmiche, C. Ell, R. Fiocca and T. Lind. (2008, discussion 1654–5; Oct). Medical or surgical management of GERD patients with Barrett's esophagus: The LOTUS trial 3-year experience. J. Gastrointest. Surg. 12(10), pp. 1646–1654. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18709511.PubMedCrossRefGoogle Scholar
  65. 65.
    A. Ortiz, L. F. Martinez de Haro, P. Parrilla, G. Morales, J. Molina, J. Bermejo, R. Liron and J. Aguilar, “Conservative treatment versus antireflux surgery in Barrett’s oesophagus: long-term results of a prospective study.” Br. J. Surg., vol. 83, pp. 274–278, Feb, 1996.PubMedCrossRefGoogle Scholar
  66. 66.
    M. Rossi, M. Barreca, N. de Bortoli, C. Renzi, S. Santi, A. Gennai, M. Bellini, F. Costa, M. Conio and S. Marchi, “Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.” Ann. Surg., vol. 243, pp. 58–63, Jan, 2006.PubMedCrossRefGoogle Scholar
  67. 67.
    D. Epstein, L. Bojke, M. J. Sculpher and g. REFLUX trial. 2009, BMJ 339 pp. b2576. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19654097.
  68. 68.
    E. Y. Chang, C. D. Morris, A. K. Seltman, R. W. O’Rourke, B. K. Chan, J. G. Hunter and B. A. Jobe, “The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review,” Ann. Surg., vol. 246, pp. 11–21, Jul, 2007.PubMedCrossRefGoogle Scholar
  69. 69.
    J. Lagergren and P. Viklund, “Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux?.” World J. Surg., vol. 31, pp. 465–469, Mar, 2007.PubMedCrossRefGoogle Scholar
  70. 70.
    Oberg S. Wenner J. Johansson J. Walther B. Willén R, “Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma.” Ann. Surg., vol. 242, pp. 49–54, Jul, 2005.PubMedCrossRefGoogle Scholar
  71. 71.
    D. E. Fleischer, R. Odze, B. F. Overholt, J. Carroll, K. J. Chang, A. Das, J. Goldblum, D. Miller, C. J. Lightdale, J. Peters, R. Rothstein, V. K. Sharma, D. Smith, V. Velanovich, H. Wolfsen and G. Triadafilopoulos. (2010, Jul). The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig. Dis. Sci. 55(7), pp. 1918–1931. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=20405211.PubMedCrossRefGoogle Scholar
  72. 72.
    B. J. Reid, R. C. Haggitt, C. E. Rubin, G. Roth, C. M. Surawicz, G. Van Belle, K. Lewin, W. M. Weinstein, D. A. Antonioli and H. Goldman, “Observer variation in the diagnosis of dysplasia in Barrett’s esophagus.” Hum. Pathol., vol. 19, pp. 166–178, Feb, 1988.PubMedCrossRefGoogle Scholar
  73. 73.
    N. J. Shaheen, P. Sharma, B. F. Overholt, H. C. Wolfsen, R. E. Sampliner, K. K. Wang, J. A. Galanko, M. P. Bronner, J. R. Goldblum, A. E. Bennett, B. A. Jobe, G. M. Eisen, M. B. Fennerty, J. G. Hunter, D. E. Fleischer, V. K. Sharma, R. H. Hawes, B. J. Hoffman, R. I. Rothstein, S. R. Gordon, H. Mashimo, K. J. Chang, V. R. Muthusamy, S. A. Edmundowicz, S. J. Spechler, A. A. Siddiqui, R. F. Souza, A. Infantolino, G. W. Falk, M. B. Kimmey, R. D. Madanick, A. Chak and C. J. Lightdale. (2009, May 28). Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 360(22), pp. 2277–2288. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19474425.PubMedCrossRefGoogle Scholar
  74. 74.
    S. Wani, S. R. Puli, N. J. Shaheen, B. Westhoff, S. Slehria, A. Bansal, A. Rastogi, H. Sayana and P. Sharma. (2009, Feb). Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: A meta-analysis and systematic review. Am. J. Gastroenterol. 104(2), pp. 502–513. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19174812.PubMedCrossRefGoogle Scholar
  75. 75.
    A. Das, C. Wells, H. J. Kim, D. E. Fleischer, M. D. Crowell and V. K. Sharma. (2009, May). An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy 41(5), pp. 400–408. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19418393.PubMedCrossRefGoogle Scholar
  76. 76.
    H. J. Stein, M. Feith, B. L. Bruecher, J. Naehrig, M. Sarbia and J. R. Siewert, “Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection.” Ann. Surg., vol. 242, pp. 566–573, discussion 573–5; Oct, 2005.PubMedGoogle Scholar
  77. 77.
    H. Fujita, S. Sueyoshi, H. Yamana, K. Shinozaki, U. Toh, Y. Tanaka, T. Mine, M. Kubota, K. Shirouzu, A. Toyonaga, H. Harada, S. Ban, M. Watanabe, Y. Toda, E. Tabuchi, N. Hayabuchi and H. Inutsuka, “Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy.” World J. Surg., vol. 25, pp. 424–431, Apr, 2001.PubMedCrossRefGoogle Scholar
  78. 78.
    C. G. Peyre, S. R. DeMeester, C. Rizzetto, N. Bansal, A. L. Tang, S. Ayazi, J. M. Leers, J. C. Lipham, J. A. Hagen and T. R. DeMeester, “Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and Barrett with high-grade dysplasia.” Ann. Surg., vol. 246, pp. 665–671, discussion 671–4; Oct, 2007.PubMedCrossRefGoogle Scholar
  79. 79.
    M. Vieth, C. Ell, L. Gossner, A. May and M. Stolte, “Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia.” Endoscopy, vol. 36, pp. 776–781, Sep, 2004.PubMedCrossRefGoogle Scholar
  80. 80.
    B. J. Dunkin, J. Martinez, P. A. Bejarano, C. D. Smith, K. Chang, A. S. Livingstone and W. S. Melvin. (2006, Jan). Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg. Endosc. 20(1), pp. 125–130. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=16333533.PubMedCrossRefGoogle Scholar
  81. 81.
    H. Heinrich and P. Bauerfeind, “Endoscopic mucosal resection for staging and therapy of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third,” Recent Results Cancer Res., vol. 182, pp. 85–91, 2010.PubMedCrossRefGoogle Scholar
  82. 82.
    A. Das, V. Singh, D. E. Fleischer and V. K. Sharma. (2008, Jun). A comparison of endoscopic treatment and surgery in early esophageal cancer: An analysis of surveillance epidemiology and end results data. Am. J. Gastroenterol. 103(6), pp. 1340–1345. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18510606.PubMedCrossRefGoogle Scholar
  83. 83.
    J. Zehetner, S. R. DeMeester, J. A. Hagen, S. Ayazi, F. Augustin, J. C. Lipham and T. R. DeMeester. (2011, Jan). Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 141(1), pp. 39–47. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21055772.PubMedCrossRefGoogle Scholar
  84. 84.
    D. K. Rex, O. W. Cummings, M. Shaw, M. D. Cumings, R. K. Wong, R. S. Vasudeva, D. Dunne, E. Y. Rahmani and D. J. Helper, “Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn.” Gastroenterology, vol. 125, pp. 1670–1677, Dec, 2003.PubMedCrossRefGoogle Scholar
  85. 85.
    D. A. Corley, A. Kubo, T. R. Levin, G. Block, L. Habel, G. Rumore, C. Quesenberry and P. Buffler. (2009, Feb). Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: A large community-based study, 1994–2006. Gut 58(2), pp. 182–188. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18978173.PubMedCrossRefGoogle Scholar
  86. 86.
    L. B. Gerson, K. Shetler and G. Triadafilopoulos, “Prevalence of Barrett’s esophagus in asymptomatic individuals.” Gastroenterology, vol. 123, pp. 461–467, Aug, 2002.PubMedCrossRefGoogle Scholar
  87. 87.
    J. A. Abrams, S. Fields, C. J. Lightdale and A. I. Neugut. (2008, Jan). Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin. Gastroenterol. Hepatol. 6(1), pp. 30–34. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18063419.PubMedCrossRefGoogle Scholar
  88. 88.
    R. M. Zagari, L. Fuccio, M. A. Wallander, S. Johansson, R. Fiocca, S. Casanova, B. Y. Farahmand, C. C. Winchester, E. Roda and F. Bazzoli. (2008, Oct). Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: The loiano-monghidoro study. Gut 57(10), pp. 1354–1359. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=18424568.PubMedCrossRefGoogle Scholar
  89. 89.
    B. Westhoff, S. Brotze, A. Weston, C. McElhinney, R. Cherian, M. S. Mayo, H. J. Smith and P. Sharma, “The frequency of Barrett’s esophagus in high-risk patients with chronic GERD.” Gastrointest. Endosc., vol. 61, pp. 226–231, Feb, 2005.PubMedCrossRefGoogle Scholar
  90. 90.
    S. J. Veldhuyzen van Zanten, A. B. Thomson, A. N. Barkun, D. Armstrong, N. Chiba, R. J. White, S. Escobedo and P. Sinclair, “The prevalence of Barrett’s oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy.” Aliment. Pharmacol. Ther., vol. 23, pp. 595–599, Mar 1, 2006.PubMedCrossRefGoogle Scholar
  91. 91.
    N. Ishimura, Y. Amano and Y. Kinoshita. (2009, Oct). Endoscopic definition of esophagogastric junction for diagnosis of Barrett’s esophagus: Importance of systematic education and training. Dig. Endosc. 21(4), pp. 213–218. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=19961518.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2011

Authors and Affiliations

  • Erin W. Gilbert
    • 1
  • Renato A. Luna
    • 1
  • Vincent L. Harrison
    • 1
  • John G. Hunter
    • 1
  1. 1.Department of Surgery, School of MedicineOregon Health Sciences UniversityPortlandUSA

Personalised recommendations